PolynovoCALZF 74 Gross Margin % is 89.11% as of Dec. 2025, which is 6% below its 10-year median of 94.67. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Polynovo ranks better than 96.89% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Polynovo's Gross Profit for the
six
months ended in Dec. 2025 was $41.57 Mil. Polynovo's Revenue for the
six
months ended in Dec. 2025 was $46.65 Mil. Therefore, Polynovo's Gross Margin % for the quarter that ended in Dec. 2025 was 89.11%.
The historical rank and industry rank for Polynovo's Gross Margin % or its related term are showing as below:
CALZF'
s Gross Margin % Range Over the Past 10 Years
Min: 88.94 Med: 94.67 Max: 124.49
Current: 91.52
During the past 13 years, the highestGross Margin % of Polynovo was 124.49%. The lowest was 88.94%. And the median was 94.67%.
CALZF's Gross Margin % is ranked better than 96.89% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs CALZF: 91.52
Polynovo had a gross margin of 89.11% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Polynovo was 0.50% per year.
Polynovo (OTCPK:CALZF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Polynovo had a gross margin of 89.11% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Polynovo Gross Margin % Related Terms
Polynovo Gross Margin % Historical Data
* Premium members only.
The historical data trend for Polynovo's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Polynovo's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Polynovo (CALZF) has a Gross Margin % of 89.11% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Polynovo and its competitors. This is near median its historical median of 94.67. Over the past decade, Polynovo's Gross Margin % has ranged from 88.94 to 124.49. According to the industry distribution chart, Polynovo ranks #25 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is Polynovo's Gross Margin % too high?
Polynovo's current Gross Margin % of 89.11% is near median its 10-year median of 94.67. Over the past 10 years, this metric has ranged from a low of 88.94 to a high of 124.49. The Medical Devices & Instruments industry median Gross Margin % is 51.94. Polynovo's value of 89.11% is 71.6% above this industry median. Based on the distribution chart, Polynovo ranks #25 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #25 out of 805 companies for Gross Margin %. This places Polynovo in the top 3% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.94. Polynovo's value of 89.11% is 71.6% above this benchmark. Historically, Polynovo's own Gross Margin % has ranged from 88.94 to 124.49 over the past decade. While the company's 10-year median is 94.67 vs. the industry median of 51.94, Polynovo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current Gross Margin % of 89.11% is 71.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Gross Margin % is 89.11%, which is near median its own 10-year median of 94.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current Gross Margin % is 89.11%, which is near median its 10-year median of 94.67 and 71.6% above the Medical Devices & Instruments industry median of 51.94. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Polynovo (CALZF), the current Gross Margin % is 89.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Gross Margin %: 89.11% (near median its 10-year median of 94.67)
GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
Industry Position: 71.6% above the Medical Devices & Instruments median (#25 of 805)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
